|
|
|
|
|
|
|
|
|
|
medical news
....As part of an ongoing clinical trial at Rutgers Cancer Institute exploring rare and poor prognosis cancers, investigators sought to identify genomic alterations in 69 patients with gynecologic cancers that were not responding to standard care. In collaboration with Foundation Medicine, Inc. of Cambridge, Massachusetts, tissue specimens were analyzed through Next Generation Sequencing technology. Study outcomes for 64 of the cases were available and showed an average 4.97 genomic alterations per tumor....
"Through genomic profiling, we're identifying alterations that may not have otherwise been visible through standard laboratory testing.
Annual Meeting of the American Association for Cancer Research (AACR)
Source: Rutgers Cancer Institute of New Jersey
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.